A Microbiological Study of with Special Reference to Multidrug Resistance

Overview

Journal J Lab Physicians

Specialty Pathology

Date 2022 Aug 19

PMID 35982877

Authors

Langamba Angom Longjam

Dechen Chomu Tsering

Dipmala Das

Affiliations

Soon will be listed here.

Abstract

The outbreak of ( ) is mainly reported to be a notorious pathogens at health-care settings. It is the major problem on the health-care system with high morbidity and mortality rates because of the broad range of antibiotic resistance and lack of understanding the mechanism of developing new antibiotic resistance rapidly. It emphasizes the importance of local surveillance in describing or understanding and predicting microbial resistance patterns so that there will be limited use of antibiotics by developing strategies to control the extensive use of antimicrobial chemotherapy in clinical environment, which is still considered as one of the factors in the emergence of multidrug resistance microorganisms. The study aims to detect the occurrence rate of infections from various clinical samples, identify the resistance levels to different groups of antimicrobial agents, and the occurrence rate of multidrug resistant (MDR) clinical isolates from a tertiary hospital in Durgapur, West Bengal, India. The study was performed in the Department of Microbiology of the IQ City Medical College and Hospital, Durgapur, West Bengal, India, for the 24 months duration, that is, from January 1, 2018 to December 31, 2019. Altogether 15,800 clinical samples consisting of endotracheal tube aspirates, sputum, pus, blood, catheter tips, urine, tissue, and other body fluids were studied. from clinical samples were identified by its characteristic colonies (nonlactose fermenting, glistening, small mucoid colonies), Gram-staining pattern (Gram-negative coccobacillus), and standard biochemical reactions. It was further confirmed in the Department of Microbiology of the Healthworld Hospital, Durgapur, West Bengal, India, by Vitek2 compact system (bioMerieux, Inc., Durham, North Carolina, United States). Antibiotic susceptibility testing was performed using automated broth microdilutions by Vitek2 compact system (bioMerieux, Inc.) and Kirby-Bauer disk diffusion test on Mueller-Hinton Agar (HiMedia). Nonrepetitive 289 were isolated from various clinical samples. A total of 277 (96%) isolates of were MDR strains. was mostly isolated from the intensive care unit department and was found to be the most MDR type in the tertiary care hospital by this study.

Citing Articles

Unraveling Whole-Genome Sequence and Functional Characterization of PH3.

Zhang X, Liang J, Zhang D, Wang L, Ye S Foods. 2024; 13(22).

PMID: 39593971 PMC: 11593290. DOI: 10.3390/foods13223555.

Molecular Characterization of Class A-ESBLs, Class B-MBLs, Class C-AmpC, and Class D-OXA Carbapenemases in MDR Acinetobacter baumannii Clinical Isolates in a Tertiary Care Hospital, West Bengal, India.

Longjam L, Tsering D, Das D Cureus. 2023; 15(8):e43656.

PMID: 37600436 PMC: 10435264. DOI: 10.7759/cureus.43656.

References

Seifert H, Stefanik D, Wisplinghoff H . Comparative in vitro activities of tigecycline and 11 other antimicrobial agents against 215 epidemiologically defined multidrug-resistant Acinetobacter baumannii isolates. J Antimicrob Chemother. 2006; 58(5):1099-100. DOI: 10.1093/jac/dkl383. View

Wareham D, Bean D, Khanna P, Hennessy E, Krahe D, Ely A . Bloodstream infection due to Acinetobacter spp: epidemiology, risk factors and impact of multi-drug resistance. Eur J Clin Microbiol Infect Dis. 2008; 27(7):607-12. DOI: 10.1007/s10096-008-0473-y. View

Abbo A, Navon-Venezia S, Hammer-Muntz O, Krichali T, Siegman-Igra Y, Carmeli Y . Multidrug-resistant Acinetobacter baumannii. Emerg Infect Dis. 2005; 11(1):22-9. PMC: 3294361. DOI: 10.3201/eid1101.040001. View

Go E, Urban C, Burns J, Kreiswirth B, Eisner W, Mariano N . Clinical and molecular epidemiology of acinetobacter infections sensitive only to polymyxin B and sulbactam. Lancet. 1994; 344(8933):1329-32. DOI: 10.1016/s0140-6736(94)90694-7. View

Rice L . Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis. 2006; 43 Suppl 2:S100-5. DOI: 10.1086/504487. View

Hsueh P, Teng L, Chen C, Chen W, Yu C, Ho S . Pandrug-resistant Acinetobacter baumannii causing nosocomial infections in a university hospital, Taiwan. Emerg Infect Dis. 2002; 8(8):827-32. PMC: 2732518. DOI: 10.3201/eid0805.020014. View

Dijkshoorn L, Nemec A, Seifert H . An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nat Rev Microbiol. 2007; 5(12):939-51. DOI: 10.1038/nrmicro1789. View

Fernandez-Cuenca F, Martinez-Martinez L, Conejo M, Ayala J, Perea E, Pascual A . Relationship between beta-lactamase production, outer membrane protein and penicillin-binding protein profiles on the activity of carbapenems against clinical isolates of Acinetobacter baumannii. J Antimicrob Chemother. 2003; 51(3):565-74. DOI: 10.1093/jac/dkg097. View

Corbella X, Pujol M, Ayats J, Sendra M, Ardanuy C, Dominguez M . Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii. Clin Infect Dis. 1996; 23(2):329-34. DOI: 10.1093/clinids/23.2.329. View

10.

Banerjee T, Mishra A, Das A, Sharma S, Barman H, Yadav G . High Prevalence and Endemicity of Multidrug Resistant spp. in Intensive Care Unit of a Tertiary Care Hospital, Varanasi, India. J Pathog. 2018; 2018:9129083. PMC: 6051072. DOI: 10.1155/2018/9129083. View

11.

Peleg A, Seifert H, Paterson D . Acinetobacter baumannii: emergence of a successful pathogen. Clin Microbiol Rev. 2008; 21(3):538-82. PMC: 2493088. DOI: 10.1128/CMR.00058-07. View

12.

Manchanda V, Sanchaita S, Singh N . Multidrug resistant acinetobacter. J Glob Infect Dis. 2010; 2(3):291-304. PMC: 2946687. DOI: 10.4103/0974-777X.68538. View

13.

Bergogne-Berezin E . The increasing significance of outbreaks of Acinetobacter spp.: the need for control and new agents. J Hosp Infect. 1995; 30 Suppl:441-52. DOI: 10.1016/0195-6701(95)90048-9. View

14.

Souli M, Kontopidou F, Koratzanis E, Antoniadou A, Giannitsioti E, Evangelopoulou P . In vitro activity of tigecycline against multiple-drug-resistant, including pan-resistant, gram-negative and gram-positive clinical isolates from Greek hospitals. Antimicrob Agents Chemother. 2006; 50(9):3166-9. PMC: 1563514. DOI: 10.1128/AAC.00322-06. View

15.

Mehrad B, Clark N, Zhanel G, Lynch 3rd J . Antimicrobial resistance in hospital-acquired gram-negative bacterial infections. Chest. 2015; 147(5):1413-1421. PMC: 4420185. DOI: 10.1378/chest.14-2171. View

16.

Khan I, Basu A, Kiran S, Trivedi S, Pandit P, Chattoraj A . Device-Associated Healthcare-Associated Infections (DA-HAI) and the caveat of multiresistance in a multidisciplinary intensive care unit. Med J Armed Forces India. 2017; 73(3):222-231. PMC: 5533520. DOI: 10.1016/j.mjafi.2016.10.008. View

17.

Poirel L, Nordmann P . Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect. 2006; 12(9):826-36. DOI: 10.1111/j.1469-0691.2006.01456.x. View